What reimbursement for coronary revascularization with drug-eluting stents?
- 1 November 2004
- journal article
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 5 (4) , 309-316
- https://doi.org/10.1007/s10198-004-0258-x
Abstract
Coronary stents, Decision analysis, Costs, Coronary artery disease,Keywords
This publication has 14 references indexed in Scilit:
- Analysis of 1-Year Clinical Outcomes in the SIRIUS TrialCirculation, 2004
- Two-year follow-up of the RAVEL study: A randomized study with the sirolimus-eluting Bx VELOCITY stent in the treatment of patients with denovo native coronary artery lesionsJournal of the American College of Cardiology, 2003
- A break-even price calculation for the use of sirolimus-eluting stents in angioplastyClinical Therapeutics, 2003
- Do the Benefits of New Technology Outweigh the Costs?American Journal of Drug Delivery, 2003
- A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary RevascularizationNew England Journal of Medicine, 2002
- A contemporary overview of percutaneous coronary interventionsJournal of the American College of Cardiology, 2002
- Clinical and Economic Impact of Diabetes Mellitus on Percutaneous and Surgical Treatment of Multivessel Coronary Disease PatientsCirculation, 2001
- Outcomes following coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in the stent era: a prospective study of all 9890 consecutive patients operated on in Scotland over a two year periodHeart, 2001
- Comparison of Coronary-Artery Bypass Surgery and Stenting for the Treatment of Multivessel DiseaseNew England Journal of Medicine, 2001
- Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)The Lancet, 1998